Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance [0.03%]
CDK4/6抑制剂在结直肠癌中的疗效及p16表达预测药物耐药的作用
Julia S Schneider,Najib Ben Khaled,Liangtao Ye et al.
Julia S Schneider et al.
Our findings underscore p16 as a promising biomarker for predicting ribociclib responsiveness and emphasize the need for further mechanistic studies and combination therapy approaches to overcome resistance in p16high patients.
Vitamin D3 augments cytotoxic effect of Itraconazole on chronic myelogenous leukemia cell line: a synergic effect on AMPK/AKT signaling pathway [0.03%]
维生素D3增强伊曲康唑对慢性髓系白血病细胞系细胞的细胞毒效应：对AMPK/AKT信号通路的协同作用
Moein Tahvili,Vahid Nejati,Yaghub Pazhang
Moein Tahvili
Background: Growing documents suggest combination therapy as an effective tool to treat the resistant cancer cells.
Uncovering the genetic basis of Staphylococcus aureus resistance to single antimicrobial peptides and their combinations [0.03%]
揭开金黄色葡萄球菌对单个抗菌肽及其组合耐药性的遗传基础
Bar Maron,Caroline Zanchi,Paul Johnston et al.
Bar Maron et al.
Whole-genome sequencing of evolved populations revealed that combination therapy significantly reduced the overall number of mutations, and importantly, did not typically lead to broad multi-AMP resistance. Instead, resistance likely focused on one component of the combination.
Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies [0.03%]
基于铂的癌症治疗进展：通过理性联合策略克服铂抗性
Nur Aininie Yusoh,Haslina Ahmad,Katherine A Vallis et al.
Nur Aininie Yusoh et al.
The most appealing candidates for combination therapy are those that offer additive and/or synergistic effects without undesirable overlapping toxicities.
Using healthcare claims data to identify health disparities for individuals with familial hypercholesterolemia [0.03%]
利用医疗理赔数据识别家族性高胆固醇血症患者健康差距
Mary P McGowan,Chao Xing,Amit Khera et al.
Mary P McGowan et al.
White individuals were more likely to get ezetimibe, PCSK9i, or combination therapy compared to Black individuals (RDs: 0.006-0.041; ORs: 1.22-1.32). Higher income was associated with increased odds of receiving these treatments (RDs: 0.005-0.060 and ORs: 1.17-1.58 for incomes >$50,000).
Development of Thyrotoxicosis With Positive TSH Receptor Antibody and Transition to Hypothyroidism in a Patient With Unresectable Hepatocellular Carcinoma During Combined Atezolizumab and Bevacizumab Therapy: A Case Report and Review of the Literature [0.03%]
不可切除肝细胞癌患者接受阿特朱单抗联合贝伐珠单抗治疗后出现促甲状腺激素受体抗体阳性型毒性多发性硬化并转为甲状腺功能减退症：病例报告及文献回顾
Ryutaro Hidaka,Yuji Hiromatsu,Narihito Tatsumoto et al.
Ryutaro Hidaka et al.
Consequently, a combination therapy consisting of an anti-programmed cell death protein-ligand 1 (PD-L1) antibody (atezolizumab) plus bevacizumab, administered every 3 weeks, was initiated in March X+1. During three cycles of this combination therapy, the patient developed thyrotoxicosis.
Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade [0.03%]
超越细胞毒性T细胞：重新编程的调节性T细胞有助于双重检查点阻断治疗的响应
Tullia C Bruno,Anthony R Cillo
Tullia C Bruno
Next, they found that LAG3hi models were unresponsive to anti-PD1 alone but responsive to combination therapy with anti-PD1 + anti-LAG3.
Host-defence caerin 1.1 and 1.9 peptides suppress B16 melanoma growth by inducing apoptosis and disrupting lipid metabolism [0.03%]
宿主防御肽caerin 1.1和1.9通过诱导凋亡和扰乱脂质代谢来抑制B16黑素瘤生长
Jiawei Fu,Xinyi Song,Rongmi Mo et al.
Jiawei Fu et al.
These findings suggest that caerin peptides exert anti-cancer effects through multifaceted mechanisms, including modulation of lipid metabolism and immune activation, positioning caerin peptides as promising candidates for combination therapy in melanoma and potentially other malignancies.
Post-COVID-19 severe Pneumocystis jirovecii pneumonia in a non-HIV and immunocompetent patient: A case report and literature review [0.03%]
新型冠状病疫情期间免疫功能正常的非艾滋病成人患者出现新型隐球菌肺炎一例及文献复习
Zhi-Yang Xu,Wei Ouyang,Jin-Liang Liu et al.
Zhi-Yang Xu et al.
The patient recovered successfully and was discharged following combination therapy with trimethoprim/sulfamethoxazole and corticosteroids.
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases [0.03%]
针对突变型p53的CD8 TCR疗法结合CD4 TCR预防癌症复发和微转移病灶的发展
Vasiliki Anastasopoulou,Hans Schreiber,Ching-En Lee et al.
Vasiliki Anastasopoulou et al.
The combination therapy also prevented the development of macrometastases from cancer cells that had already spread to the lung at the time of TCR-therapy. Macrometastases were only observed after monotherapy.
耗时 0.27196 秒，为您在
48229835
条记录里面共找到 10000 篇文章 [XML]